Skip to main content

Table 1 Epidemiological data and comorbidities of patients included in the study distributed by diagnostic category; [n (%)] except where indicated

From: Repeated Aspergillusisolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection?

 

Total

Colonised

Aspergillosis

   

Probable

Proven

Probable + Proven

No. Patients

245

106

125

14

139

Age (mean ± SD)

68.7 ± 15.2

69.1 ± 16.1

68.9 ± 14.6

64.1 ± 14.5

68.4 ± 14.6

Males

171 (69.8)

67 (63.2)

94 (75.2)

10 (71.4)

104 (74.8)a

Comorbidities b

     

 COPD

173 (70.6)

73 (68.9)

91 (72.8)

9 (64.3)

100 (71.9)

   Gold III + IV c

111 (67.3)

40 (57.2)

66 (76.7)a

5 (55.6)

71 (74.7)a

 Diabetes Mellitus II

43 (17.6)

19 (17.9)

23 (18.4)

1 (7.1)

24 (17.3)

 Congestive heart failure

45 (18.4)

13 (12.3)

27 (21.6)

5 (35.7)a

32 (23.0)a

 Malignancies

38 (15.5)

10 (9.4)

27 (21.6)a

1 (7.1)

28 (20.1)a

 Renal impairment

24 (9.8)

10 (9.4)

12 (9.6)

2 (14.3)

14 (10.1)

Charlson (mean ± SD)

2.61 ± 2.16

2.42 ± 2.03

2.81 ± 2.29

2.21 ± 1.76

2.75 ± 2.75

APACHE (mean ± SD)

13.16 ± 6.86

11.63 ± 6.12

14.13 ± 6.67a

16.14 ± 10.90

14.33 ± 7.18a

ICU admission at any time during hospital stay

58 (23.7)

15 (14.2)

36 (28.8)a

7 (50.0)a

43 (30.9)a

  1. ap ≤ 0.050 vs. colonised; bpresent in ≈ > 10% total patients; camong patients with available data (165 patients in total: 70 colonized, 86 probable and 9 proven).